Panel Discussion: Review of the Last 12 Months of Development of Alpha Emitting Therapies

Time: 5:30 pm
day: Day Two


  • Discuss how Lutathera has changed the game for RLT developers and what it has taught us about RLT’s place on the wider oncology field
  • Explore what key learnings have been uncovered by VISION trial and other recent analyses of alphaemitters’ clinical applications